JP2017521496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521496A5 JP2017521496A5 JP2017520743A JP2017520743A JP2017521496A5 JP 2017521496 A5 JP2017521496 A5 JP 2017521496A5 JP 2017520743 A JP2017520743 A JP 2017520743A JP 2017520743 A JP2017520743 A JP 2017520743A JP 2017521496 A5 JP2017521496 A5 JP 2017521496A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- compound
- hydrogen
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 198
- 229910052739 hydrogen Inorganic materials 0.000 claims description 85
- 239000001257 hydrogen Substances 0.000 claims description 85
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 53
- 150000002431 hydrogen Chemical class 0.000 claims description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
- 125000004429 atom Chemical group 0.000 claims description 38
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 38
- -1 amino, carboxy Chemical group 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 125000004104 aryloxy group Chemical group 0.000 claims description 28
- 125000002252 acyl group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 11
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 229940124530 sulfonamide Drugs 0.000 claims description 8
- 150000003456 sulfonamides Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 9
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 8
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 8
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 0 C*[C@]1(*)C(*)(*)[C@](C(*)Oc2ccc(CC**)c(*)c2)C1* Chemical compound C*[C@]1(*)C(*)(*)[C@](C(*)Oc2ccc(CC**)c(*)c2)C1* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016473P | 2014-06-24 | 2014-06-24 | |
| US62/016,473 | 2014-06-24 | ||
| PCT/US2015/037478 WO2015200514A2 (en) | 2014-06-24 | 2015-06-24 | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186914A Division JP7105851B2 (ja) | 2014-06-24 | 2020-11-10 | Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521496A JP2017521496A (ja) | 2017-08-03 |
| JP2017521496A5 true JP2017521496A5 (https=) | 2018-08-02 |
| JP6793640B2 JP6793640B2 (ja) | 2020-12-02 |
Family
ID=53525293
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520743A Active JP6793640B2 (ja) | 2014-06-24 | 2015-06-24 | Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド |
| JP2020186914A Active JP7105851B2 (ja) | 2014-06-24 | 2020-11-10 | Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020186914A Active JP7105851B2 (ja) | 2014-06-24 | 2020-11-10 | Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10590065B2 (https=) |
| EP (2) | EP4494702A3 (https=) |
| JP (2) | JP6793640B2 (https=) |
| KR (1) | KR102536408B1 (https=) |
| CN (1) | CN106536498A (https=) |
| AU (2) | AU2015279926B2 (https=) |
| CA (2) | CA3289739A1 (https=) |
| CL (2) | CL2016003276A1 (https=) |
| CO (1) | CO2017000552A2 (https=) |
| EA (1) | EA201790070A1 (https=) |
| IL (1) | IL249712B (https=) |
| MX (2) | MX388516B (https=) |
| NZ (1) | NZ728482A (https=) |
| SG (2) | SG10201811574YA (https=) |
| WO (1) | WO2015200514A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| MX388516B (es) | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| CN108478568B (zh) * | 2018-02-01 | 2020-08-28 | 华中农业大学 | 一种香豆素类化合物在制备单胺氧化酶抑制剂中的用途 |
| EP3749675B1 (en) | 2018-02-07 | 2025-12-31 | Reata Pharmaceuticals, Inc. | CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE |
| JP7508375B2 (ja) * | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| KR102175125B1 (ko) * | 2018-12-28 | 2020-11-05 | 울산과학기술원 | 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| JP5401329B2 (ja) | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| ES2647889T3 (es) * | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| WO2012163054A1 (zh) | 2011-11-16 | 2012-12-06 | 华为技术有限公司 | 一种微波预失真信号生成方法和装置 |
| SMT201900660T1 (it) * | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| MX388516B (es) | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
-
2015
- 2015-06-24 MX MX2019015888A patent/MX388516B/es unknown
- 2015-06-24 SG SG10201811574YA patent/SG10201811574YA/en unknown
- 2015-06-24 CN CN201580033560.XA patent/CN106536498A/zh active Pending
- 2015-06-24 JP JP2017520743A patent/JP6793640B2/ja active Active
- 2015-06-24 KR KR1020177001978A patent/KR102536408B1/ko active Active
- 2015-06-24 WO PCT/US2015/037478 patent/WO2015200514A2/en not_active Ceased
- 2015-06-24 EA EA201790070A patent/EA201790070A1/ru unknown
- 2015-06-24 AU AU2015279926A patent/AU2015279926B2/en active Active
- 2015-06-24 EP EP24196960.9A patent/EP4494702A3/en not_active Withdrawn
- 2015-06-24 CA CA3289739A patent/CA3289739A1/en active Pending
- 2015-06-24 US US15/321,289 patent/US10590065B2/en active Active
- 2015-06-24 MX MX2016017133A patent/MX388515B/es unknown
- 2015-06-24 SG SG11201610677XA patent/SG11201610677XA/en unknown
- 2015-06-24 CA CA2952029A patent/CA2952029C/en active Active
- 2015-06-24 EP EP15735815.1A patent/EP3160977A2/en not_active Withdrawn
- 2015-06-24 NZ NZ728482A patent/NZ728482A/en unknown
-
2016
- 2016-12-21 CL CL2016003276A patent/CL2016003276A1/es unknown
- 2016-12-22 IL IL249712A patent/IL249712B/en active IP Right Grant
-
2017
- 2017-01-23 CO CONC2017/0000552A patent/CO2017000552A2/es unknown
-
2018
- 2018-08-17 CL CL2018002367A patent/CL2018002367A1/es unknown
-
2020
- 2020-01-29 US US16/776,091 patent/US11098008B2/en active Active
- 2020-11-10 JP JP2020186914A patent/JP7105851B2/ja active Active
-
2021
- 2021-02-15 AU AU2021200969A patent/AU2021200969B2/en active Active
- 2021-07-14 US US17/375,882 patent/US11708319B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521496A5 (https=) | ||
| JP7096592B2 (ja) | Ｊａｋ阻害剤およびこれらの利用 | |
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| JP6862404B2 (ja) | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 | |
| RU2008150324A (ru) | Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний | |
| JP2010529147A5 (https=) | ||
| PH12014502531B1 (en) | Benzamine derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| JP2018502900A5 (https=) | ||
| RU2013145869A (ru) | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| CN109069461A (zh) | 与髓源性抑制细胞相关的病症的治疗方法 | |
| AU2011334592C1 (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| JP2020504120A5 (https=) | ||
| EP3661924A1 (en) | Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia | |
| UY32435A (es) | 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona útil en el tratamiento de enfermedades pulmonares | |
| CN111035641B (zh) | Gzd824及其药学上可接受的盐在治疗疾病中的新应用 | |
| JP2022502378A5 (https=) | ||
| JP2009533466A5 (https=) | ||
| WO2022028429A1 (zh) | 用于根除癌症干细胞并诱导damp介导的抗肿瘤免疫反应的一组新型copi/arf1-脂解途径抑制剂和化合物 | |
| CN112043722A (zh) | Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用 | |
| WO2015002293A1 (ja) | Ｗｎｔシグナル阻害剤 | |
| US20210308106A1 (en) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | |
| KR20240161853A (ko) | 신규한 화합물 및 이의 간암 치료 용도 | |
| CA2831771A1 (en) | Polyamide compound and pharmaceutical composition for treating mitochondrial genetic diseases | |
| CN115944740A (zh) | 靶向hif-1/cbs在三阴性乳腺癌中的应用 | |
| CN105829291B (zh) | 与疼痛有关的化合物及医药组合物 |